274
Participants
Start Date
January 16, 2024
Primary Completion Date
December 3, 2025
Study Completion Date
December 3, 2025
Survodutide
once weekly subcutaneous injection
Placebo matching survodutide
once weekly subcutaneous injection
Hosokawa Surgery Clinic, Aichi, Nagoya
Nagoya City University Hospital, Aichi, Nagoya
Chiba University Hospital, Chiba, Chiba
Gifu University Hospital, Gifu, Gifu
Jiyugaoka Yamada Clinic, Hokkaido, Obihiro
Yamasaki Family Clinic, Hyogo, Amagasaki
Kobe University Hospital, Hyogo, Kobe
Motomachi Takatsuka Naika Clinic, Kanagawa, Yokohama
Morinagaueno Clinic, Kumamoto, Kumamoto
Yoshimura Clinic, Kumamoto, Kumamoto
Medical Corporation KEISEIKAI Kajiyama Clinic, Kyoto, Kyoto
Ijinkai Takeda General Hospital, Kyoto, Kyoto
Osaka Metropolitan University Hospital, Osaka, Osaka
OCROM Clinic, Osaka, Suita
Saino Clinic, Saitama, Tokorozawa
Dojinkinenkai Meiwa Hospital, Tokyo, Chiyoda-ku
Suidoubashi Medical Clinic, Tokyo, Chiyoda-ku
Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku
Tokyo Center Clinic, Tokyo, Chuo-ku
Fukuwa Clinic, Tokyo, Chuo-ku
Tokyo Asbo Clinic, Tokyo, Chuo-ku
New Medical Research System Clinic, Tokyo, Hachioji
Shimamura Kinen Hospital, Tokyo, Nerima-ku
Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku
HS Clinic, Tokyo, Shinjuku-ku
ToCROM Clinic, Tokyo, Shinjyuku-ku
Shinei Medical Healthcare Clinic, Tokyo, Suginami-ku
Ikebukuro Metropolitan Clinic, Tokyo, Toshima-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY